GCLabs

Search for Test Items

HRD

GC Labs code	F082	Test Field	Human genetics
Compulsory forms	Oncology requisition and consent form, GC Genome Informed consent for genetic testing

GC Labs code

F082

Test Field

Human genetics

Compulsory forms

Oncology requisition and consent form, GC Genome Informed consent for genetic testing

Information

Test method	NGS (Next generation sequencing)
Specimen (mL)	Unstained slide 16 section & H&E slide
Specimen storage	Ambient
Specimen stability	-
Test schedule	Mon-Fri
Analytical time (day)	21

Test method

NGS (Next generation sequencing)

Specimen (mL)

Unstained slide 16 section & H&E slide

Specimen storage

Ambient

Specimen stability

Test schedule

Mon-Fri

Analytical time (day)

Reference range/Unit	[Unstain slide] See comments in the report
Clinical Significance	This assay uses next generation sequencing (NGS) technology to detect homologous recombination deficiency based on analysis of genomic instability and BRCA1/BRCA2 gene mutation. In tumor cells, the DNA damage is not properly repaired and the cell continues to divide. A case in which DNA repair process does not occur due to problem in homologous recombination function or mutation in BRCA gene is referred to as Homologous Recombination Deficiency (HRD). Tumors with HRD are particularly susceptible to specific targeted cancer therapies such as the PARP inhibitors.
Remark	[Specimen Handling] Unstained slide: Diameter ≥ 1.0 cm, thickness 10 μm [Precautions & Cautions] ① Mark the "lesion area" on the H&E slide ② Submission is acceptable only when tumor cellularity (number of malignant nuclei / number of all nuclei) ≥ 30%

Reference range/Unit

 [Unstain slide]
See comments in the report

Clinical Significance

This assay uses next generation sequencing (NGS) technology to detect homologous recombination deficiency based on analysis of genomic instability and BRCA1/BRCA2 gene mutation. In tumor cells, the DNA damage is not properly repaired and the cell continues to divide. A case in which DNA repair process does not occur due to problem in homologous recombination function or mutation in BRCA gene is referred to as Homologous Recombination Deficiency (HRD). Tumors with HRD are particularly susceptible to specific targeted cancer therapies such as the PARP inhibitors.

Remark

[Specimen Handling]
Unstained slide: Diameter ≥ 1.0 cm, thickness 10 μm

[Precautions & Cautions]
① Mark the "lesion area" on the H&E slide
② Submission is acceptable only when tumor cellularity (number of malignant nuclei / number of all nuclei) ≥ 30%